BioSpace News Archive

Shimmer Research, a global leader in wearable technology for research applications, today announced that the Open Wearables Initiative (OWEAR) has uploaded its open source software and datasets database for wearable sensors and other connected health technologies to its website at www.owear.org.

This release was previously disseminated on May 27, 2020 at 16:03 ET. The date and time details for the conferences have been updated.

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced plans to expand the potential use of Oxbryta® (voxelotor) for the treatment of sickle cell disease (SCD) in children ages 4 to 11 years, following a Type B meeting with the U.S. Food and Drug Administration (FDA).

Cerecor Inc. (Nasdaq: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare pediatric and orphan diseases, announced today that it intends to offer for sale shares of its common stock in an underwritten public offering.

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported results for the third quarter ended April 30, 2020.

Almost twenty years after deciphering the human genome, our understanding of human disease is still far from complete. One of the most powerful and versatile tools to better understand biology and disease-relevant processes is the use of well-characterized small chemical modulators of protein function. The new EUbOPEN consortium aims

Cognition Therapeutics, Inc. , a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease and other neurodegenerative disorders, today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the Company a grant (number R01AG065248) expected to total $75.8 million over five years to support a 540-patient Phase 2 study of CT1812 in indi

Adaptation Health, in partnership with Acumen America and the Center for Health Care Strategies announce the selected companies and panelists to a 3-part virtual demo day series: Responding to COVID-19 and Beyond: Demo Day for Medicaid Innovation.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that it will host a key opinion leader (KOL) call on intratumoral therapy with self-delivering RNAi at 8

Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has received CE Mark Certification in the European Union for its SurVeil™ drug-coated balloon (DCB). “I am excited about the potential of the SurVeil DCB to improve the